Contents

Physical Properties in Drug Design .................................................. 1
Robert J. Young

Improving Solubility via Structural Modification ......................... 69
Michael A. Walker

Tactics to Avoid Inhibition of Cytochrome P450s .......................... 107
Andrew G. Leach

Avoiding PXR and CAR Activation and CYP3A4 Enzyme Induction .... 159
Michael W. Sinz

Strategies for Minimisation of the Cholestatic Liver Injury
Liability Posed by Drug-Induced Bile Salt Export Pump (BSEP)
Inhibition ...................................................................................... 191
J. Gerry Kenna, Simone H. Stahl, and Tobias Noeske

Drug Discovery vs hERG ................................................................. 225
Derek J Leishman and Zoran Rankovic

Drug-Induced Phospholipidosis: Prediction, Detection, and
Mitigation Strategies ...................................................................... 261
Umesh M Hanumegowda and Alicia Regueiro-Ren

The Influence of Bioisosteres in Drug Design: Tactical Applications
to Address Developability Problems .............................................. 283
Nicholas A. Meanwell

Erratum to: Improving Solubility via Structural Modification ........... 383
Michael A. Walker

Erratum to: Drug Discovery vs hERG ............................................. 385
Derek J. Leishman and Zoran Rankovic
Erratum to: Drug-Induced Phospholipidosis: Prediction, Detection, and Mitigation Strategies ................................. 387
Umesh M. Hanumegowda and Alicia Regueiro-Ren

Erratum to: The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems .................. 389
Nicholas A. Meanwell

Index ................................................................. 391